{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:38:52Z","timestamp":1791866332638,"version":"4.3.4"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-CD19 chimeric antigen receptor T (CAR-T) cells have demonstrated activity against relapsed\/refractory lymphomas. Cytokine release syndrome (CRS) and immune effector cell \u2013 associated neurotoxicity syndrome (ICANS) are well-known complications. Tocilizumab, a monoclonal antibody targeting the interleukin-6 (IL-6) receptor was administered 1 hour prior to infusion of anti-CD19 CAR-T cells with CD3\u03b6\/4-1BB costimulatory signaling used to treat non-Hodgkin lymphoma patients. Relapsed\/refractory lymphoma patients treated with anti-CD19 CAR-T cells were included in this analysis. Cytokine plasma levels were measured by electrochemiluminescence before lymphodepleting chemotherapy, prior to infusion and then on days 2, 4,6, and 14 days after treatment. Twenty patients were treated. Cell products included locally manufactured anti-CD19 CAR-T (n=18) and tisagenlecleucel (n=2). There were no adverse events attributed to tocilizumab. Ten patients had grade 1\u20132 CRS at a median of 4 (range 3-7) days. There were no cases of grade \u22653 CRS. Five patients had ICANS, grade 1 (n=4) and grade 4 (n=1). Laboratory studies obtained prior to lymphodepleting chemotherapy were comparable between patients with and without CRS, except for interleukin (IL)-15 plasma concentrations. patients with CRS had higher post-infusion ferritin and C reactive protein, with more marked increases in inflammatory cytokines, including IL-6, IL-15, IFN-\u03b3, fractalkine and MCP-1. Fifteen patients (75%) achieved CR and 2 (10%), PR. One-year OS and PFS estimates were 83% and 73%. Prophylactic tocilizumab was associated with low CRS incidence and severity. There were no adverse events associated with tocilizumab, no increase in frequency or severity of ICANS and excellent disease control and overall survival.<\/jats:p>","DOI":"10.3389\/fimmu.2021.745320","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T17:55:49Z","timestamp":1634147749000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":121,"title":["Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Paolo F.","family":"Caimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Pacheco Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folashade","family":"Otegbeye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Kleinsorge Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schiavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Zamborsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Boughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Hillian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Reese-Koc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Maschan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boro","family":"Dropulic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafick-Pierre","family":"Sekaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent Advances in CAR T-Cell Toxicity: Mechanisms, Manifestations and Management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B2","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The Pharmacology of Second-Generation Chimeric Antigen Receptors","volume":"14","author":"van der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-136834","article-title":"Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed\/Refractory (R\/R) Indolent Non-Hodgkin Lymphoma (iNHL)","volume":"136","author":"Jacobson","year":"2020","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSCEND NHL 001): A Multicentre Seamless Design Study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1889510","article-title":"Brexucabtagene Autoleucel for the Treatment of Relapsed\/Refractory Mantle Cell Lymphoma","volume":"21","author":"Mian","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B11","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41392-020-00256-x","article-title":"The Model of Cytokine Release Syndrome in CAR T-Cell Treatment for B-Cell non-Hodgkin Lymphoma","volume":"5","author":"Wei","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome After CD19 Chimeric Antigen Receptor-Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-Derived IL-1 and IL-6 Are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3153","article-title":"IL-6 as a Keystone Cytokine in Health and Disease","volume":"16","author":"Hunter","year":"2015","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int J Biol Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S223468","article-title":"Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01941","article-title":"Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-Hodgkin Lymphoma","volume":"11","author":"Jackson","year":"2020","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric Antigen Receptor T-Cell Therapy - Assessment and Management of Toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric Estimation From Incomplete Observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"B25","doi-asserted-by":"publisher","first-page":"JCO2002477","DOI":"10.1200\/JCO.20.02477","article-title":"Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial","volume":"39","author":"Kadauke","year":"2021","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001304","article-title":"Grading and Management of Cytokine Release Syndrome in Patients Treated With Tisagenlecleucel in the JULIET Trial","volume":"4","author":"Schuster","year":"2020","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952","article-title":"Comparing CAR T-Cell Toxicity Grading Systems: Application of the ASTCT Grading System and Implications for Management","volume":"4","author":"Pennisi","year":"2020","journal-title":"Blood Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-World Evidence of Tisagenlecleucel for Pediatric Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3881","article-title":"Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127490","article-title":"A Multicenter Retrospective Analysis of Clinical Outcomes, Toxicities, and Patterns of Use in Institutions Utilizing Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed\/Refractory Aggressive B-Cell Lymphomas","volume":"134","author":"Riedell","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143114","article-title":"CAR-T Therapy for Lymphoma With Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome Without Excessive Neurologic Toxicity","volume":"136","author":"Caimi","year":"2020","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine Release Syndrome Associated With Chimeric-Antigen Receptor T-Cell Therapy: Clinicopathological Insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2016.03.005","article-title":"Measuring IL-6 and sIL-6R in Serum From Patients Treated With Tocilizumab and\/or Siltuximab Following CAR T Cell Therapy","volume":"434","author":"Chen","year":"2016","journal-title":"J Immunol Methods"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-155846","article-title":"Mechanisms and Pathologic Significances in Increase in Serum Interleukin-6 (IL-6) and Soluble IL-6 Receptor After Administration of an Anti-IL-6 Receptor Antibody, Tocilizumab, in Patients With Rheumatoid Arthritis and Castleman Disease","volume":"112","author":"Nishimoto","year":"2008","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated With CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity After Adoptive Immunotherapy With CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2414","article-title":"Advances in CAR T Therapy for Hematologic Malignancies","volume":"40","author":"Freyer","year":"2020","journal-title":"Pharmacotherapy"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary Results of Prophylactic Tocilizumab After Axicabtageneciloleucel (Axi-Cel; KTE-C19) Treatment for Patients With Refractory,Aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-130370","article-title":"Local Manufacture of CD19 CAR-T Cells Using an Automated Closed-System: Robust Manufacturing and High Clinical Efficacy With Low Toxicities","volume":"134","author":"Molostova","year":"2019","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(17)30108-4","article-title":"EASIX in Patients With Acute Graft-Versus-Host Disease: A Retrospective Cohort Analysis","volume":"4","author":"Luft","year":"2017","journal-title":"Lancet Haematol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX Predicts Severe Cytokine Release Syndrome and Neurotoxicity After Chimeric Antigen Receptor T Cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and Ferritin in Addition to the EASIX Score Predict CAR-T-Related Toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388","article-title":"B-Cell Depletion and Remissions of Malignancy Along With Cytokine-Associated Toxicity in a Clinical Trial of Anti-CD19 Chimeric-Antigen-Receptor-Transduced T Cells","volume":"119","author":"Kochenderfer","year":"2012","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-828343","article-title":"Preinfusion Polyfunctional Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With Clinical Outcomes in NHL","volume":"132","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"107318","DOI":"10.1016\/j.intimp.2020.107318","article-title":"Biological Effects of IL-15 on Immune Cells and Its Potential for the Treatment of Cancer","volume":"91","author":"Zhang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing Mtorc1 Activity and Preserving Their Stem Cell Memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Effector Cell-Related Adverse Events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745320\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T02:47:22Z","timestamp":1673491642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.745320\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":47,"alternative-id":["10.3389\/fimmu.2021.745320"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.745320","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"article-number":"745320"}}